CureVac N.V. (CVAC): Price and Financial Metrics

CureVac N.V. (CVAC): $13.87

-0.07 (-0.50%)

POWR Rating

Component Grades













Add CVAC to Watchlist
Sign Up

Industry: Biotech



in industry

CVAC Stock Price Chart Interactive Chart >

Price chart for CVAC

CVAC Price/Volume Stats

Current price $13.87 52-week high $76.22
Prev. close $13.94 52-week low $12.90
Day low $13.72 Volume 482,373
Day high $14.15 Avg. volume 648,142
50-day MA $16.29 Dividend yield N/A
200-day MA $27.76 Market Cap 2.60B

CureVac N.V. (CVAC) Company Bio

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

CVAC Latest News Stream

Event/Time News Detail
Loading, please wait...

CVAC Latest Social Stream

Loading social stream, please wait...

View Full CVAC Social Stream

Latest CVAC News From Around the Web

Below are the latest news stories about CureVac NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | February 16, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | February 15, 2022

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

Yahoo | February 11, 2022

CureVac (CVAC) Gets a Buy Rating from JMP Securities

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), with a price target of $52.00. The company's shares closed last Thursday at $18.64, close to its 52-week low of $16.34. According to, Buchanan is ranked 0 out of 5 stars with an average return of -13.4% and a 32.7% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma. Currently, the analyst consensus on CureVac is a Hold with an average price target of $36.00, representing a 90.5% upside.

Catie Powers on TipRanks | February 10, 2022

CureVac starts Phase 1 trial for experimental flu shot developed with GSK

Shares of CureVac gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline . The open-label study plans to enroll 240 adults. CureVac had previously tried to develop a COVID-19 vaccine but instead decided last year to scrap those plans and instead focus on developing a second-generation COVID-19 shot with GSK. CureVac''s stock has tumbled 83.7% over the past year, while the broader S&P 500 is up 17.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

MarketWatch | February 10, 2022

Read More 'CVAC' Stories Here

CVAC Price Returns

1-mo N/A
3-mo -29.27%
6-mo -59.57%
1-year -79.44%
3-year N/A
5-year N/A
YTD -59.57%
2021 -57.68%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4269 seconds.